Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in mCRPC
NCT02146833Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Karyopharm Therapeutics Inc.. Started May 2014; status: terminated.
02
Drugs
selinexor
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02146833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146833.